Eichemberger Rius Flávia, Santa Cruz Guindalini Rodrigo, Viana Danilo, Salomão Júlia, Gallo Laila, Freitas Renata, Bertolacini Cláudia, Taniguti Lucas, Imparato Danilo, Antunes Flávia, Sousa Gabriel, Achjian Renan, Fukuyama Eric, Gregório Cleandra, Ventura Iuri, Gomes Juliana, Taniguti Nathália, Maistro Simone, Krieger José Eduardo, Zheng Yonglan, Huo Dezheng, Olopade Olufunmilayo I, Azevedo Koike Folgueira Maria Aparecida, Schlesinger David
Mendelics, Sao Paulo 02511-000, SP, Brazil.
Comprehensive Center for Precision Oncology (C2PO), Centro de Investigação Translacional em Oncologia (CTO), Departamento de Radiologia e Oncologia, Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo 01246-000, SP, Brazil.
Diagnostics (Basel). 2025 Apr 25;15(9):1098. doi: 10.3390/diagnostics15091098.
: Brazil has a highly admixed population. Polygenic risk scores (PRSs) have mostly been developed from European population studies, and their application to other populations is challenging. To assess the use of PRS for breast cancer (BC) risk in Brazil, we evaluated four PRSs in the Brazilian population. We analyzed a Brazilian cohort composed of 6206 women with a history of breast cancer and 8878 unphenotyped adults as controls. Genomic variants were imputed from exomes, and scores were calculated for all samples. After individuals with known pathogenic or likely pathogenic variants in , , , , or genes, and first-degree relatives of the probands were excluded, 5598 cases and 8767 controls remained. Four PRS models were compared, and PRS achieved the best performance, with an odds ratio (OR) of 1.43 per standard deviation increase ( value < 0.001) and an OR of 1.88 ( value < 0.001) for the top decile. PRS also performed well for different ancestry groups: East Asian majority (OR 1.59, value 0.004), Non-European majority (OR 1.45, value < 0.001), and European majority (OR 1.43, value < 0.001). Among the different PRSs, PRS and PRS could be validated in our Brazilian cohort, with the latter exhibiting the best performance. While further clinical studies are necessary to guide clinical practice, this work represents an important step toward improving BC precision medicine in Brazil.
巴西拥有高度混合的人口。多基因风险评分(PRSs)大多是根据欧洲人群研究得出的,将其应用于其他人群具有挑战性。为了评估PRS在巴西乳腺癌(BC)风险评估中的应用,我们在巴西人群中评估了四种PRS。我们分析了一个巴西队列,其中包括6206名有乳腺癌病史的女性和8878名未表现出相关表型的成年人作为对照。从外显子组中推断出基因组变异,并计算所有样本的评分。在排除携带已知致病或可能致病变异的基因(如 、 、 、 或 )的个体以及先证者的一级亲属后,剩下5598例病例和8767名对照。比较了四种PRS模型,PRS表现最佳,每增加一个标准差的优势比(OR)为1.43( 值<0.001),最高十分位数的OR为1.88( 值<0.001)。PRS在不同血统组中也表现良好:东亚血统占多数的组(OR 1.59, 值0.004)、非欧洲血统占多数的组(OR 1.45, 值<0.001)和欧洲血统占多数的组(OR 1.43, 值<0.001)。在不同的PRS中,PRS和PRS可以在我们的巴西队列中得到验证,后者表现最佳。虽然还需要进一步的临床研究来指导临床实践,但这项工作是巴西在改善BC精准医学方面迈出的重要一步。